Examining the shift from fast answers to verified intelligence in enterprise AI.
Updated
January 8, 2026 6:33 PM
Startup employee reviewing business metrics on an AI-powered dashboard. PHOTO: FREEPIK
Neuron7.ai, a company that builds AI systems to help service teams resolve technical issues faster, has launched Neuro. It is a new kind of AI agent built for environments where accuracy matters more than speed. From manufacturing floors to hospital equipment rooms, Neuro is designed for situations where a wrong answer can halt operations.
What sets Neuro apart is its focus on reliability. Instead of relying solely on large language models that often produce confident but inaccurate responses, Neuro combines deterministic AI — which draws on verified, trusted data — with autonomous reasoning for more complex cases. This hybrid design helps the system provide context-aware resolutions without inventing answers or “hallucinating”, a common issue that has made many enterprises cautious about adopting agentic AI.
“Enterprise adoption of agentic AI has stalled despite massive vendor investment. Gartner predicts 40% of projects will be canceled by 2027 due to reliability concerns”, said Niken Patel, CEO and Co-Founder of Neuron7. “The root cause is hallucinations. In service operations, outcomes are binary. An issue is either resolved or it is not. Probabilistic AI that is right only 70% of the time fails 30% of your customers and that failure rate is unacceptable for mission-critical service”.
That concern shaped how Neuro was built. “We use deterministic guided fixes for known issues. No guessing, no hallucinations — and reserve autonomous AI reasoning for complex scenarios. What sets Neuro apart is knowing which mode to use. While competitors race to make agents more autonomous, we're focused on making service resolution more accurate and trusted”, Patel explained.
At the heart of Neuro is the Smart Resolution Hub, Neuron7’s central intelligence layer that consolidates service data, knowledge bases and troubleshooting workflows into one conversational experience. This means a technician can describe a problem — say, a diagnostic error in an MRI scanner — and Neuro can instantly generate a verified, step-by-step solution. If the problem hasn’t been encountered before, it can autonomously scan through thousands of internal and external data points to identify the most likely fix, all while maintaining traceability and compliance.
Neuro’s architecture also makes it practical for real-world use. It integrates seamlessly with enterprise systems such as Salesforce, Microsoft, ServiceNow and SAP, allowing companies to embed it within their existing support operations. Early users of Neuron7’s platform have reported measurable improvements — faster resolutions, higher customer satisfaction and reduced downtime — thanks to guided intelligence that scales expert-level problem solving across teams.
The timing of Neuro’s debut feels deliberate. As organizations look to move past the hype of generative AI, trust and accountability have become the new benchmarks. AI systems that can explain their reasoning and stay within verifiable boundaries are emerging as the next phase of enterprise adoption.
“The market has figured out how to build autonomous agents”, Patel said. “The unsolved problem is building accurate agents for contexts where errors have consequences. Neuro fills that gap”.
Neuron7 is building a system that knows its limits — one that reasons carefully, acts responsibly and earns trust where it matters most. In a space dominated by speculation, that discipline may well redefine what “intelligent” really means in enterprise AI.
Keep Reading
How a Korean biotech startup is using AI to move drug discovery from trial-and-error to precision design
A close up of a protein structure model. PHOTO: UNSPLASH
For decades, drug discovery has relied on trial and error, with scientists testing thousands of molecules to find one that works. Galux, a South Korean biotech startup, is changing that by using AI to design proteins from scratch. This method, called “de novo” design, makes it possible to build precise new therapies instead of searching through existing ones.
The company recently announced a US$29 million Series B funding round, bringing its total capital to US$47 million.This significant investment attracted a substantial roster of institutional backers, including the Korea Development Bank (KDB), Yuanta Investment, SL Investment and NCORE Ventures. These firms joined existing investors such as InterVest, DAYLI Partners and PATHWAY Investment, as well as new participants including SneakPeek Investments, Korea Investment & Securities and Mirae Asset Securities.
At the core of the company’s work is a platform called GaluxDesign. Unlike many AI tools that only predict how existing proteins fold, this system uses deep learning and physics to create entirely new therapeutic antibodies. This “from scratch” approach lets the team go after so-called “undruggable” proteins. These are targets that traditional small-molecule drugs can’t reach because they lack clear binding pockets. By designing proteins to fit these complex shapes, Galux aims to unlock treatments that have stayed out of reach for decades. And that’s exactly why investors are paying attention.
The pharmaceutical industry is actively looking for faster and more efficient ways to develop new drugs, and Galux is built for exactly that. The company connects its AI platform directly to its own wet lab, where designs can be tested in real time. Each result feeds straight back into the system, sharpening the next round of models. This continuous loop speeds up discovery and improves precision at every step. It’s also why partners like Celltrion, LG Chem and Boehringer Ingelheim are already working with Galux.
Galux is no longer just trying to make drugs that stick to a target. The company now wants its AI to design medicines that actually work in the body and can be made at scale. In simple terms, a drug has to do more than bind to a disease—it must be stable, safe and strong enough to change how the illness behaves. Galux is moving into tougher targets such as ion channels and GPCRs. These play key roles in heart function and sensory signals. Ultimately, the goal is to show that AI-driven design can turn complex biology into real treatments. And instead of hunting blindly for a solution, the team is building exactly what they need.